The Supervisory Board of Fresenius Medical Care AG, the world's leading provider of products and services for individuals with renal disease, has appointed Cassie McLean (48) as a member of the Management Board, effective 1 August 2026. Ms. McLean will serve as Chief Executive Officer of the operating segment Care Delivery. She succeeds Craig Cordola (54), who previously served as Chief Executive Officer of Care Delivery.

McLean joined Fresenius Medical Care in August 2025 as President, Fresenius Kidney Care. She will now assume direct accountability for the global clinic business, including Fresenius Kidney Care in the U.S. and Care Delivery International. The role has been reshaped to create more direct accountability for operational execution and business performance.

Michael Sen, Chairman of the Supervisory Board, commented: "We welcome Cassie McLean to the Management Board of Fresenius Medical Care. She brings deep dialysis expertise, strong leadership, and a clear understanding of the performance drivers across the clinic business. Her appointment reflects the Board's confidence in her ability to accelerate progress in Care Delivery." He added: "I would like to thank Craig Cordola for his contributions and commitment to patients and wish him all the best in the future."

Helen Giza, CEO and Chair of the Management Board, said: "Since joining Fresenius Medical Care last year, Cassie has moved quickly to significantly improve operational visibility, implement a new structure and tools to drive accountability, and strengthen talent in the U.S. clinic business. I am confident in her ability to execute our strategy and deliver our mid-term financial aspirations in Care Delivery."